Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2021 Filed Apr 15, 2021 20:20 UTC |
Helsel DaveSVP Global Operations and R&D
|
SaleCommon Stock | 3,500 | $23.93 | $83,755.00 |
DisclosureSEC source: 0001567619-21-008147 · doc1.xml · nonDerivative · entry 1 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.90 to $24.05, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:53 UTC |
DONNELLY HOWARD WDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,726 | $0.00 Strike: $14.64 | $0.00 |
DisclosureSEC source: 0001567619-21-007649 · doc1.xml · derivative · entry 3 DONNELLY HOWARD W · CIK 0001212978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,726 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 8/12/2015, 8/12/2016, 8/12/2017 and 8/12/2018, respectively. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:53 UTC |
DONNELLY HOWARD WDirector
|
Tax withholdingCommon Stock | 3,621 | $23.15 | $83,826.15 |
DisclosureSEC source: 0001567619-21-007649 · doc1.xml · nonDerivative · entry 2 DONNELLY HOWARD W · CIK 0001212978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,974 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:53 UTC |
DONNELLY HOWARD WDirector
|
Exercise / conversionCommon Stock | 5,726 | $14.64 | $83,828.64 |
DisclosureSEC source: 0001567619-21-007649 · doc1.xml · nonDerivative · entry 1 DONNELLY HOWARD W · CIK 0001212978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2021 Filed Feb 4, 2021 21:27 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 527 | $19.24 | $10,139.48 |
DisclosureSEC source: 0001567619-21-002187 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,746 F1 · shares: The exempt disposition of 527 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on February 3, 2020. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:44 UTC |
ROSENZWEIG RICHARD CSVP and General Counsel
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 62,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-002156 · doc1.xml · derivative · entry 2 ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2031-02-01 F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on February 1, 2022, such that 25% of the options will vest on each of February 1, 2022, 2023, 2024 and 2025. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:44 UTC |
ROSENZWEIG RICHARD CSVP and General Counsel
|
GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002156 · doc1.xml · nonDerivative · entry 1 ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · shares: The acquisition of 11,000 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 11,000 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on February 1, 2022, such that 25% of the restricted stock units will vest on each of February 1, 2022, 2023, 2024 and 2025. Read SEC document |
| January 20, 2021 Filed Jan 21, 2021 15:15 UTC |
JOHNSON WESLEYDirector
|
SaleCommon Stock | 6,500 | $18.53 | $120,445.00 |
DisclosureSEC source: 0001567619-21-001303 · doc1.xml · nonDerivative · entry 1 JOHNSON WESLEY · CIK 0001258791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,911 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.02 to $18.89, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 23:05 UTC |
Helsel DaveSVP Global Operations and R&D
|
Tax withholdingCommon Stock | 733 | $14.29 | $10,474.57 |
DisclosureSEC source: 0001567619-20-021448 · doc1.xml · nonDerivative · entry 1 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,615 F1 · shares: The exempt disposition of 733 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on December 18, 2017. Read SEC document |
| October 31, 2020 Filed Nov 3, 2020 16:22 UTC |
Centea ScottSVP/GM, VIT
|
Tax withholdingCommon Stock | 849 | $10.62 | $9,016.38 |
DisclosureSEC source: 0001567619-20-018615 · doc1.xml · nonDerivative · entry 1 Centea Scott · CIK 0001823973 · SVP/GM, VIT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,004 F1 · shares: The exempt disposition of 849 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on October 31, 2019. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 20:14 UTC |
Trowbridge Stephen AEVP and CFO
|
PurchaseCommon Stock | 1,013 | $9.38 | $9,501.94 |
DisclosureSEC source: 0001567619-20-014905 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,273 Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 21:27 UTC |
Clemmer James CDirector · President and CEO
|
PurchaseCommon Stock | 40,000 | $8.26 | $330,400.00 |
DisclosureSEC source: 0001567619-20-014068 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,319 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.24 to $8.26, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 20:38 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 1,799 | $8.80 | $15,831.20 |
DisclosureSEC source: 0001567619-20-013825 · doc1.xml · nonDerivative · entry 2 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,319 F2 · shares: The exempt disposition of 1,799 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 20:43 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 292 | $8.80 | $2,569.60 |
DisclosureSEC source: 0001567619-20-013828 · doc1.xml · nonDerivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,260 F2 · shares: The exempt disposition of 292 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 27, 2020 Filed Jul 28, 2020 20:27 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 259 | $8.80 | $2,279.20 |
DisclosureSEC source: 0001567619-20-013822 · doc1.xml · nonDerivative · entry 2 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,724 F2 · shares: The exempt disposition of 259 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
| July 26, 2020 Filed Jul 28, 2020 20:38 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 1,876 | $8.80 | $16,508.80 |
DisclosureSEC source: 0001567619-20-013825 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,118 F1 · shares: The exempt disposition of 1,876 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 26, 2020 Filed Jul 28, 2020 20:43 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 314 | $8.80 | $2,763.20 |
DisclosureSEC source: 0001567619-20-013828 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,552 F1 · shares: The exempt disposition of 314 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 26, 2020 Filed Jul 28, 2020 20:27 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 283 | $8.80 | $2,490.40 |
DisclosureSEC source: 0001567619-20-013822 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,983 F1 · shares: The exempt disposition of 283 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:33 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 1,483 | $9.21 | $13,658.43 |
DisclosureSEC source: 0001567619-20-013546 · doc1.xml · nonDerivative · entry 2 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,994 F2 · shares: The exempt disposition of 1,483 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:36 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 152 | $9.21 | $1,399.92 |
DisclosureSEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,866 F3 · shares: The exempt disposition of 152 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:36 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 248 | $9.21 | $2,284.08 |
DisclosureSEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,018 F2 · shares: The exempt disposition of 248 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:34 UTC |
Helsel DaveSVP Global Operations and R&D
|
Tax withholdingCommon Stock | 155 | $9.21 | $1,427.55 |
DisclosureSEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 3 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,348 F3 · shares: The exempt disposition of 153 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:34 UTC |
Helsel DaveSVP Global Operations and R&D
|
Tax withholdingCommon Stock | 207 | $9.21 | $1,906.47 |
DisclosureSEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 2 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,501 F2 · shares: The exempt disposition of 207 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:31 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 76 | $9.21 | $699.96 |
DisclosureSEC source: 0001567619-20-013545 · doc1.xml · nonDerivative · entry 3 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,266 F3 · shares: The exempt disposition of 76 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 18, 2020 Filed Jul 21, 2020 23:31 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 224 | $9.21 | $2,063.04 |
DisclosureSEC source: 0001567619-20-013545 · doc1.xml · nonDerivative · entry 2 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,342 F2 · shares: The exempt disposition of 224 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:33 UTC |
Clemmer James CDirector · President and CEO
|
Tax withholdingCommon Stock | 2,131 | $9.46 | $20,159.26 |
DisclosureSEC source: 0001567619-20-013546 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,477 F1 · shares: The exempt disposition of 2,131 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:36 UTC |
Trowbridge Stephen AEVP and CFO
|
Tax withholdingCommon Stock | 354 | $9.46 | $3,348.84 |
DisclosureSEC source: 0001567619-20-013548 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,266 F1 · shares: The exempt disposition of 354 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:34 UTC |
Helsel DaveSVP Global Operations and R&D
|
Tax withholdingCommon Stock | 254 | $9.46 | $2,402.84 |
DisclosureSEC source: 0001567619-20-013547 · doc1.xml · nonDerivative · entry 1 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,708 F1 · shares: The exempt disposition of 254 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019. Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 23:31 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 262 | $9.46 | $2,478.52 |
DisclosureSEC source: 0001567619-20-013545 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,566 F1 · shares: The exempt disposition of 262 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 23:28 UTC |
REED JAN STERNDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013373 · doc1.xml · nonDerivative · entry 1 REED JAN STERN · CIK 0001124181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,979 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 22:52 UTC |
Auen Eileen O'SheaDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013361 · doc1.xml · nonDerivative · entry 1 Auen Eileen O'Shea · CIK 0001428073 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,663 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 19:22 UTC |
Meteny Dennis SDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013371 · doc1.xml · nonDerivative · entry 1 Meteny Dennis S · CIK 0001289336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,401 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 23:11 UTC |
JOHNSON WESLEYDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013367 · doc1.xml · nonDerivative · entry 1 JOHNSON WESLEY · CIK 0001258791 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,411 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 22:58 UTC |
DONNELLY HOWARD WDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013363 · doc1.xml · nonDerivative · entry 1 DONNELLY HOWARD W · CIK 0001212978 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,869 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 23:17 UTC |
Licitra Karen ADirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013369 · doc1.xml · nonDerivative · entry 1 Licitra Karen A · CIK 0001754757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,380 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 23:06 UTC |
Gould Kevin JDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013365 · doc1.xml · nonDerivative · entry 1 Gould Kevin J · CIK 0001504093 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,504 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:35 UTC |
Clemmer James CDirector · President and CEO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 160,237 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001567619-20-013438 · doc1.xml · derivative · entry 3 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,237 Underlying: Common Stock · 160,237 shares Expires 2030-07-14 F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:35 UTC |
Clemmer James CDirector · President and CEO
|
GrantPerformance Right · Derivative | 108,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013438 · doc1.xml · derivative · entry 2 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,871 Underlying: Common Stock · 108,871 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:35 UTC |
Clemmer James CDirector · President and CEO
|
GrantCommon Stock | 54,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013438 · doc1.xml · nonDerivative · entry 1 Clemmer James C · CIK 0001476700 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,608 F1 · shares: This acquisition of 54,435 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 54,435 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:44 UTC |
Trowbridge Stephen AEVP and CFO
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 44,510 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001567619-20-013440 · doc1.xml · derivative · entry 3 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,510 Underlying: Common Stock · 44,510 shares Expires 2030-07-14 F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:44 UTC |
Trowbridge Stephen AEVP and CFO
|
GrantPerformance Right · Derivative | 30,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013440 · doc1.xml · derivative · entry 2 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,242 Underlying: Common Stock · 30,242 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:44 UTC |
Trowbridge Stephen AEVP and CFO
|
GrantCommon Stock | 15,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013440 · doc1.xml · nonDerivative · entry 1 Trowbridge Stephen A · CIK 0001624250 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,620 F1 · shares: This acquisition of 15,121 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 15,121 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:43 UTC |
Helsel DaveSVP Global Operations and R&D
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 22,196 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001567619-20-013439 · doc1.xml · derivative · entry 3 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,196 Underlying: Common Stock · 22,196 shares Expires 2030-07-14 F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:43 UTC |
Helsel DaveSVP Global Operations and R&D
|
GrantPerformance Right · Derivative | 15,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013439 · doc1.xml · derivative · entry 2 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,081 Underlying: Common Stock · 15,081 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:43 UTC |
Helsel DaveSVP Global Operations and R&D
|
GrantCommon Stock | 7,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013439 · doc1.xml · nonDerivative · entry 1 Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,962 F1 · shares: This acquisition of 7,540 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 7,540 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:34 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,800 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001567619-20-013437 · doc1.xml · derivative · entry 3 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 19,800 shares Expires 2030-07-14 F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:34 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
GrantPerformance Right · Derivative | 13,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013437 · doc1.xml · derivative · entry 2 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,453 Underlying: Common Stock · 13,453 shares Expires not disclosed F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited. Read SEC document |
| July 14, 2020 Filed Jul 18, 2020 01:34 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
GrantCommon Stock | 6,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-013437 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,828 F1 · shares: This acquisition of 6,726 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 6,726 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024. Read SEC document |
| July 14, 2020 Filed Sep 16, 2020 20:17 UTC |
Tarnoff Michael EDirector
|
GrantCommon Stock | 15,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-016796 · doc1.xml · nonDerivative · entry 1 Tarnoff Michael E · CIK 0001603289 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,323 F1 · shares: The acquisition of 15,323 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 15,323 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/14/2021. Read SEC document |
| May 23, 2020 Filed May 28, 2020 00:56 UTC |
Campbell Chad ThomasSVP/GM, Vascular Access
|
Tax withholdingCommon Stock | 826 | $11.21 | $9,259.46 |
DisclosureSEC source: 0001567619-20-011253 · doc1.xml · nonDerivative · entry 1 Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,102 F1 · shares: This exempt disposition of 826 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.